Vaccine delivery to animals

被引:73
作者
Bowersock, TL [1 ]
Martin, S [1 ]
机构
[1] Pharmacia & Upjohn Anim Hlth, Kalamazoo, MI 49001 USA
关键词
adjuvants; aluminum hydroxide; drug delivery systems; ISCOMS; liposomes; microparticles; microspheres; naked DNA; recombinant vaccines; transgenic plant vaccines; vaccination;
D O I
10.1016/S0169-409X(99)00015-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For many years vaccination of animals has been practiced to prevent infectious diseases using inactivated organisms or modified live organisms. The Live vaccines were effective but lacked safety. The vaccines made with inactivated organisms required an adjuvant to induce an immune response that was not as effective as either the clinical disease or live vaccines. An 'ideal' vaccine would induce effective immunity specific for the type of infection, have long duration, require minimal or no boosters, have impeccable safety, would not induce adverse reactions, and be easy to administer. The desire to meet these criteria, and especially safety, has resulted in the development of vaccines that do not depend on the use of the viable disease agent. The emphasis on subunit or inactivated vaccines that meet the desired criteria of a perfect vaccine has resulted in a critical need for better adjuvants and delivery systems. This has resulted in a technological innovation revolution with development of a wide array of different technologies to generate effective vaccines. This review will describe the historical relevance of adjuvants used for parenterally administered inactivated/subunit vaccines as well as describe some of the exciting technological advances including adjuvants (ISCOMS), delivery systems (recombinant vectors, microparticles), and novel approaches (transgenic plants, naked DNA) that are currently being, or will be used in the future, in the search for better, more effective vaccines that meet the current and future needs of veterinary medicine. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:167 / 194
页数:28
相关论文
共 216 条
[1]   SENSITIVITY AND SPECIFICITY OF MYCOPLASMA-GALLISEPTICUM AGGLUTINATION ANTIGENS PREPARED FROM MEDIUM WITH ARTIFICIAL LIPOSOMES SUBSTITUTING FOR SERUM [J].
AHMAD, I ;
KLEVEN, SH ;
AVAKIAN, AP ;
GLISSON, JR .
AVIAN DISEASES, 1988, 32 (03) :519-526
[2]   MICROENCAPSULATION OF DNA WITHIN ALGINATE MICROSPHERES AND CROSS-LINKED CHITOSAN MEMBRANES FOR IN-VIVO APPLICATION [J].
ALEXAKIS, T ;
BOADI, DK ;
QUONG, D ;
GROBOILLOT, A ;
ONEILL, I ;
PONCELET, D ;
NEUFELD, RJ .
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 1995, 50 (01) :93-106
[3]  
Alexandersen S, 1996, ACTA VET SCAND, P89
[4]   LIPOSOMES AS CARRIERS OF ANTIGENS AND ADJUVANTS [J].
ALVING, CR .
JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 140 (01) :1-13
[5]  
AMKRAUT AA, 1976, FED PROC, V35, P675
[6]   USE OF LIPOSOME-IMMUNOPOTENTIATED EXOPOLYSACCHARIDE AS A COMPONENT OF AN OVINE MASTITIS STAPHYLOCOCCAL VACCINE [J].
AMORENA, B ;
BASELGA, R ;
ALBIZU, I .
VACCINE, 1994, 12 (03) :243-249
[7]  
Anderson A O, 1987, Adv Exp Med Biol, V216B, P1781
[8]   Duration of protective immunity against ovine haemonchosis following vaccination with the nematode gut membrane antigen H11. [J].
Andrews, SJ ;
Rolph, TP ;
Munn, EA .
RESEARCH IN VETERINARY SCIENCE, 1997, 62 (03) :223-227
[9]  
APRILE MA, 1966, C J PUBLIC HEALTH, V57, P343
[10]  
AVRAMEAS S, 1976, ANN INST PASTEUR IMM, VC127, P551